Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Novartis taps Homology Medicines for viral-based gene editing

The duo aims to edit genetic blood and eye diseases using adeno-associated viruses (AAVs) rather than CRISPR

by Ryan Cross
November 13, 2017

Article:

This article has been sent to the following recipient: